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Lactic acidosis is commonly observed in clinical situations such as shock and sepsis, as a result of tissue hypoperfusion and hypoxia.
Lymphoma and leukemia are among other clinical situations where lactic acidosis has been reported. We present a case of a 59-
year-old female with lactic acidosis who was found to have aggressive B-cell lymphoma. There have been 29 cases of lymphoma
induced lactic acidosis reported thus far; however all reported cases have abnormal vital signs or concomitant medical conditions
that may lead to lactic acidosis. The pathogenesis of malignancy-induced lactic acidosis is not well understood; however associated
factors include increased glycolysis, increased lactate production by cancer cells, and decreased hepatic clearance of lactate. When
it occurs, lactic acidosis is a poor prognostic sign in these patients. Prompt diagnosis and treatment of underlying lymphoma or
leukemia remains the only way to achieve complete resolution of lactic acidosis in these patients.
Copyright © 2009 Farn Huei Chan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Lactic acidosis is a common cause of an anion gap acidosis
that often carries a significant risk for mortality. Lactic
acidosis most commonly results from an imbalance between
oxygen delivery and oxygen demand (Type A). However,
it can also occur in the absence of a recognizable impair-
ment in systemic oxygen delivery, resulting from impaired
oxidative phosphorylation (Type B). Type B lactic acidosis
is associated with numerous conditions, including inborn
errors of metabolism, drugs and toxins, systemic diseases
(i.e., diabetes and sepsis), and less commonly, malignancy.
Lactic acidosis has been reported in cases of lymphoma
and leukemia. The exact pathophysiology and the best way
to manage lactic acidosis in this setting remain unclear. We
present a case and review the literature relating to lactic
acidosis in lymphoma.
2. Case Report
A previously healthy 59-year-old high school teacher pre-
sented with severe fatigue, generalized weakness, decreased
appetite, weight loss, and increased abdominal swelling for
2 months. She reported no fever, night sweats, cough, or
urinary symptoms. On physical examination, she appeared
cachectic with temporal muscle wasting. Blood pressure was
113/38, heart rate was 134/min, respiratory rate was 22/min,
temperature was 98.6◦F, and she was not hypoxic on room
air. The spleen tip was palpated at 10 cm below the left costal
margin. Physical exam findings were otherwise normal.
Laboratory data revealed sodium 134 mmol/L, potas-
sium 4.4 mmol/L, chloride 93 mmol/L, carbon dioxide
<10 mmol/L, anion gap >31 , blood urea nitrogen (BUN)
25 mg/dL, creatinine 0.6 mg/dL, and glucose 87 mg/dL.
Other pertinent labs included leukocyte count 6.4 × 109/L,
hemoglobin 4.1 g/dL, platelet count 19 × 109/L, aspartate
transaminase (AST) 103 U/L, alanine transaminase (ALT)
15 U/L, alkaline phosphatase 104 U/L, lactate dehydroge-
nase (LDH) 647 mmol/L (normal range 0.5–2.2 mmol/L),
haptoglobin 55 mg/dL, uric acid 13.6 mg/dL, and lactate
16.5 mmol/L. Arterial blood gas revealed a pH of 7.33, a
PCO2 of 21 mmHg, and PO2 of 132 mmHg, with a bicarbon-
ate of 11.2 mmol/L. Peripheral blood smear revealed no blast
cells or abnormal leukocytes. Blood cultures were negative.
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Figure 1: Computed tomography scan of the abdomen showed
massive splenomegaly and extensive lymphadenopathy . (L: liver, S:
spleen, N: lymphadenopathy).
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Figure 2: Correlation between lactate level and vital signs.
Computed tomography (CT) scan of the abdomen and pelvis
revealed massive splenomegaly measuring 25 cm craniocau-
dally, and extensive lymphadenopathy in the abdomen and
pelvis (Figure 1).
The patient was aggressively hydrated and received blood
transfusions to improve her anemia. However, she remained
tachycardic. Throughout her hospital course, her blood
pressures remained stable. No source of infection or bleeding
was identified. With these measures, lactate improved to
6.7 mmol/L but shortly after that rose to 27.7 mmol/L
(Figures 2 and 3).
While awaiting pathological diagnosis, the patient dete-
riorated clinically, and on day 4, intravenous corticosteroids
were administered for presumed high-grade lymphoma. In
addition, a sodium bicarbonate infusion and allopurinol
were initiated for tumor lysis syndrome prophylaxis.
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Figure 3: Correlation between lactate level, pH, bicarbonate,
creatinine, and hemoglobin.
Bone marrow biopsy revealed a diﬀuse (>50%) infiltrate
of cells positive for CD 45 and CD 20, negative for CD 5,
CD 10, CD 23, and cyclin D1. GTG-banding studies reveal a
very complex karyotype. However, morphologically the cells
were not large enough to be called large B-cell lymphoma.
The final diagnosis was CD 20-positive B-cell lymphoma.
Cyclophosphamide, vincristine, and prednisone were started
on day 7. On day 8, she developed respiratory distress
with new bilateral pulmonary infiltrates concerning for
adult respiratory distress syndrome and became hypotensive
requiring vasopressor support. Given the severity of the
multiple organ failure, her family decided to withdraw
support, and she died on hospital day 12. Autopsy revealed
extensive lymphoma as well as diﬀuse pulmonary, kidney,
and esophageal hemorrhage.
3. Discussion
Lactate is produced from the anaerobic metabolism of
pyruvate, which in turn is generated from glucose via gly-
colysis. Therefore, lactate production is a surrogate marker
of acidosis during a hypoxic state, and not the direct cause.
Lactic acidosis is infrequently encountered in malignancies;
yet when present portends an extremely poor prognosis [1].
Moreover, the strikingly high mortality associated with lactic
acidosis has prompted some oncologists to consider this
an oncological emergency [2]. Hematologic malignancies,
including acute leukemias and high-grade lymphomas, are
the most common neoplastic disorders associated with lactic
acidosis. Twenty nine cases of lymphoma induced lactic
acidosis have been published in English language journals
(Table 1). Seven patients experienced either a partial or
complete remission, three of whom subsequently expired
from recurrence and there is no long-term followup on an
additional two patients. As patients with malignancy induced
lactic acidosis are often criticallyill, it is diﬃcult to discern
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Table 1: Summary of all reported cases of lactic acidosis associated with lymphoma. (NR: normal range; BP: blood pressure; RR: respiratory
rate; P: pulse; T: temperature.)
Reference Age
Type of
lymphoma
Lactate
(mmol/L)
Vitals
Directed treatment
of lactic acidosis
Chemo Outcome Comments
Friedenberg
et al. [3]
75 Follicular 5.4 BP NR P104 None Yes
Died in 2
days
Friedenberg
et al. [3]
54 T-cell 12 BP 120/50 P 92 None Yes
Died in 10
weeks
Friedenberg
et al. [3]
54 Diﬀuse large
B-cell
18 BP 96/40 P118 Hemodialysis Yes
Died in 4
days
Concomitant
sepsis (presumed)
He et al. [4] 28
Natural
Killer/T-cell
11.2 NR IV Bicarbonate Yes Remission
Died from
recurrence after
undisclosed
period of time
Prikis et al.
[5]
65 Large B-cell 18 NR
IV bicarbonate and
dialysis
Yes Remission
Sustained low
eﬃciency dialysis
Dogan et al.
[6]
24 Large B-cell 33.0
BP 100/60 P 95
RR18 T 36.7 C
IV Bicarbonate and
Hemodialysis
Yes
Died within
10 days
Glasheen and
Sorensen [7]
74 Burkitt’s 15.8 NR None No
Died in 13
days
Ohtsubo
et al. [8]
77 Mantle Cell 26.3 NR IV Bicarbonate Yes Remission
DiComite
et al. [9]
64 Large B-cell 9.0 NR IV Bicarbonate Yes Died
Unclear time to
death
Sillos et al.
[1]
18 Large T-cell 15.4 NR IV bicarbonate Yes Remission
Lymphoma
recurred and died
in 7 months
Thakur et al.
[10]
82 Hodgkin’s 11.5 NR IV bicarbonate No
Died in 3
days
Yasin and
Hartranft
[11]
76 Large B-cell 13.1 NR None No
Died in 7
days
Presumed
ascending
cholangitis. Had
two exploratory
operations
Durig et al.
[12]
71 Non-
Hodgkin’s
17.4 BP 120/60 P120 IV Bicarbonate Yes
Died in 14
days
Scheuleer-
Holmes et al.
[13]
54 Non-
Hodgkin’s
16.4
BP 160/90 P 92
RR 26 T 37.1 C
IV Bicarbonate Yes
Died within 3
months
Caspar and
Oelz [14]
74 Non-
Hodgkin’s
14.8 NR None No
Died in 2
days
Caspar and
Oelz [14]
71 Non-
Hodgkin’s
12.2
BP 165/100 P
100
IV Bicarbonate Yes Remission Died in 6 months
Caspar and
Oelz [14]
34 Non-
Hodgkin’s
23.6 NR IV Bicarbonate Yes Remission
Lactic acidosis
occurred after
exploratory
operation
Doolittle
et al. [15]
19 Diﬀuse
Histiocytic
21.8
BP 90/60 P 120
RR 24, Temp
101 F
IV Bicarbonate Yes
Died in 5
weeks
Blood cultures
negative
Doolittle
et al. [15]
60 Hodgkin’s 16.3 NR IV Bicarbonate Yes
Died in 24
days
Vandermolen
et al. [16]
32 Non-
Hodgkin’s
32 NR None Yes Remission
4 Case Reports in Medicine
Table 1: Continued.
Reference Age
Type of
lymphoma
Lactate
(mmol/L)
Vitals
Directed treatment
of lactic acidosis
Chemo Outcome Comments
Johnson and
Whelan [17]
21 Non-Hodgkin’s 16.1 NR IV Bicarbonate Yes
Died in 14
days
WBC 27,700 and
presumed sepsis
Leyden et al.
[18]
47 Hodgkin’s 20.0 NR IV Bicarbonate Yes
Died within 6
days
Pneumonia
Leyden et al.
[18]
61 Non-Hodgkin’s 46.8 NR IV Bicarbonate Yes
Died in one
day
Gastrointestinal
hemorrhage with
hemoglobin of
4.0 g/dL
Nadiminti
et al. [19]
30 Hodgkin’s 14 BP 120/80 P106 IV bicarbonate Yes
Died in 4
weeks
Mintz et al.
[20]
65 Histiocytic 21.8
BP 114/66 P 124
RR 32
IV Bicarbonate No
Died in 4
days
Mintz et al.
[20]
34 Histiocytic 14.2
BP 120/75 P100
T 39C
IV Bicarbonate Yes
Died in 8
days
Mintz et al.
[20]
60 Histiocytic 5.9
BP 100/65 P 124
RR 30
None Yes
Died in 3
weeks
Mintz et al.
[20]
58 Histiocytic 4.5
BP 90/60 P 112
RR 50 T 39C
None Yes
Died in 2
weeks
Scheerer et al.
[21]
47 Hodgkin’s 8.8 BP 112/80 P110 IV bicarbonate Yes
Died in 11
days
whether the etiology of lactic acidosis is completely a result
from the malignancy and not from other potential causes
of Type A lactic acidosis (i.e., sepsis, hypotension, hypoxia,
etc.). In the patient we present above, she did not have
hypoxia or significant hypotension when the lactic acidosis
was discovered. The lactic acidosis persisted despite volume
repletion, including blood transfusions. Furthermore, we
could not identify a source of infection and her lactic acidosis
preceded her intensive care visit. However, she was anemic,
tachycardic, and tachypneic at presentation. Therefore, it is
impossible to conclude there were no additional influences
that may have led to Type A lactic acidosis. Upon reviewing
the current literature of lymphoma induced lactic acidosis,
many cases did have concomitant sepsis, anemia, surgical
procedures, or abnormal vital signs (Table 1). Accordingly,
every published case that reported vital signs had at least
one vital sign indicative of systemic inflammatory response.
As the majority of cases to date had concomitant factors
that potentially could lead to lactic acidosis, as in the case
we present above, the true incidence of lymphoma induced
lactic acidosis remains cloudy.
The pathogenesis of lactic acidosis in lymphoma is
incompletely understood and likely multifactorial. Liver
metastasis and dysfunction is often cited as a potential
cause because of reduced hepatic utilization of lactate via
gluconeogenesis [7]. However, lactic acidosis can occur in the
absence of liver dysfunction [1, 22, 23]. In fact, Sillos et al.
reported 19% of patients with lactic acidosis in the setting of
hematological malignancies did not have liver involvement
[1]. Furthermore, lactic acidosis is uncommon in patients
with cirrhosis or fulminant hepatic failure in the absence
of malignancy [24]. Accordingly, although liver dysfunction
may contribute to the development of lactic acidosis, it is
unlikely to be the sole cause. Another potential mechanism
for lactic acidosis is increased glycolytic activity, with a
subsequent increase in lactate acid generation, in cancer
cells. Further supporting this hypothesis, several cases have
been characterized by recurrent hypoglycemia, presumably
related to increased glycolysis [7, 9, 12]. Overexpression
of type II hexokinase [25], a glycolytic enzyme found in
mitochondria, or increased IGF-binding protein (IGFBP)
activity, has been implicated in the increased glycolysis in
cancer cells [1]. Finally, excessive lactate production may
result from highly aggressive tumors that simply outgrow
their blood supply [26]. In essence, there is production of
lactate from local hypoxia in the absence of any systemic
hypoxia or hypoperfusion.
Regardless of etiology, the treatment for lactic acidosis is
to discern and correct the underlying mechanism producing
the lactate, as well as to ensure adequate oxygen delivery
in cases of hypoxia. Accordingly, in malignancy derived
lactic acidosis, chemotherapy is the primary treatment
modality. As demonstrated in Table 1, the only treatment
modality that consistently leads to remission was initiation
of chemotherapy. Of the 29 reported cases of lymphoma
induced lactic acidosis, only seven went into remission, all
of whom received chemotherapy. Of the seven cases who
went into remission, the lactate levels normalized in 6 (one
case did not report what happened to the lactate levels after
chemotherapy). In five of the six cases, resolution of the
lactic acidosis occurred as early as 15 hours and up to 3
days after starting chemotherapy. In the remaining case,
the lactate level normalized weeks after chemotherapy was
introduced; however, did so within 2 days of starting salvage
chemotherapy. Thus, it is probably safe to conclude that
if lactic acidosis improves after chemotherapy, it occurs in
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timely manner. Additionally, it is conceivable that prompt
resolution of lactic acidosis could be a surrogate marker of
inducing remission.
Both intravenous (IV) bicarbonate and hemodialysis
have been used to control the lactic acidosis until chemother-
apy can treat the malignancy. The use of IV bicarbonate
as an interim treatment of profound acidosis (in either the
presence or absence of malignancy) remains a contentious
issue [27–30]. As severe acidosis can cause respiratory fatigue
and hemodynamic instability, intravenous bicarbonate is
often used to attenuate the sequelae of systemic acidosis.
However, there are potential side eﬀects from using IV
sodium bicarbonate. The most obvious of which are hyperv-
olemia and hypernatremia [31]. Additionally, sodium bicar-
bonate infusion may actually increase lactic acid production
[28]. The rise in lactate levels has been seen in human
[32] and animal [33, 34] studies. The decreased oxygen
delivery has been postulated to occur from both a reduction
in PaO2 [35] as well as increased aﬃnity of oxygen to
hemoglobin resulting from the rise in systemic pH following
IV bicarbonate infusion [36]. The eﬀect of IV bicarbonate
on mortality or lactate concentrations in the setting of
malignancy induced lactic acidosis has not been directly
studied. From our review of the literature, 20 of the 29
cases used IV bicarbonate to treat the acidosis. Two patients
received IV bicarbonate without adjunctive chemotherapy,
and both died within days. Of the 7 patients who went
into remission, 6 were on IV bicarbonate. Although it
is unlikely that bicarbonate administration provides any
mortality benefit beyond chemotherapy, this has not been
directly studied.
Renal replacement therapy (RRT), including hemodial-
ysis, peritoneal dialysis, or hemofiltration can be used
to remove lactate and correct acidosis [37]. Prikis et al.
recently reported a case of lymphoma induced lactic acidosis
successfully treated with sustained low eﬃciency dialysis
implemented as a temporary measure to correct acidosis
and hypervolemia until chemotherapy was initiated [5]. Two
other cases of lymphoma induced lactic acidosis have been
treated with hemodialysis and chemotherapy, both of whom
died within 10 days. As the prognosis of lymphoma induced
lactic acidosis is grim, the only hope for remission is starting
chemotherapy. Although IV bicarbonate and hemodialysis
can be implemented in an attempt to control the acidosis,
it must be emphasized that these measures should be viewed
as a bridge until the underlying cause is treated.
In conclusion, lactic acidosis is an ominous sign in
patients with lymphoma or leukemia. The exact pathogenesis
of this condition remains unclear. Prompt diagnosis and
early treatment of underlying lymphoma or leukemia is the
only way to achieve complete resolution of lactic acidosis in
these patients.
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